<DOC>
	<DOCNO>NCT00448097</DOCNO>
	<brief_summary>The purpose study differentiate administration Cetuximab alone vs. Cetuximab plus Docetaxel treatment non-metastatic prostate cancer surgical removal prostate .</brief_summary>
	<brief_title>Efficacy Safety Study Cetuximab Cetuximab Plus Docetaxel Treat Prostate Cancer Before Prostatectomy</brief_title>
	<detailed_description>With large number men undergo screen assay serum prostate specific antigen , urologist continue see considerable number patient locally advanced prostate disease . There high risk treatment failure patient tumor extend prostate capsule , aggressive pathology ( Gleason score 7 high ) , patient PSA great 10 ng/ml . The rationale add molecular target drug Cetuximab ( epithelial growth factor inhibitor ) , without chemotherapy Docetaxel , therapy potential demonstrate tumor shrinkage prostate , addition , micrometastatic cell . Cetuximab alone Cetuximab plus Docetaxel utilizing preprostatectomy model , adjuvant delivery Cetuximab 6 month , provide data follow point : 1. demonstration PSA response prior prostatectomy ; 2. demonstration whether change natural history , delay onset metastatic disease patient advance local prostate cancer , achieve ; 3. laboratory tissue correlation ass change proliferative , apoptosis , pathologic parameter ; 4. metabolic image utilizing CT-PET FDG ass whether useful modality exhibit response therapy , compare conventional radiographic imaging . This provide basis future development neoadjuvant chemotherapy prior prostatectomy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologic proof prostatic adenocarcinoma without evidence regional and/or distant metastasis , clinical stage T1c T2a high grade disease ( Gleason 's 810 ) initial biopsy , clinical stage T2bT2c Gleason 's grade 7 PSA â‰¥ 10ng/ml , clinical stage T3 . Recent ( &lt; 6 week prior study entry ) negative bone scan MRI abdomen pelvis . Appropriate surgical candidate radical prostatectomy performance status &lt; 2 ( Zubrod scale ) . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 platelet count &gt; 100,000 , adequate hepatic function bilirubin &lt; 1.5 mg % SGPT &lt; 2.5x upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x ULN . Patients must normal coagulation profile ( PT , PTT ) history substantial noniatrogenic bleeding diatheses . Use anticoagulant limit local use ( control central line patency ) . Patients must history congestive heart failure previous MI within last 12 month . Previous current hormonal treatment , chemotherapy , radiation therapy , immunotherapy investigational status drug . Unable tolerate transrectal ultrasound . Patients appropriate surgical candidate radical prostatectomy base evaluation coexistent medical disease compete cause death . Patients uncontrolled cardiac , hepatic , renal neurologic/psychiatric disorder eligible . Patients uncontrolled symptomatic orthostatic hypotension uncontrolled hypertension eligible . Patients HIV positive chronic hepatitis B C infection eligible . Patients oral steroid medication eligible . Patients significant arteriosclerotic disease , define previous arterial bypass claudication limit activity , history cerebrovascular event within last year ( include TIA ) eligible . Prior severe infusion reaction monoclonal antibody .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Adenocarcinoma Prostate</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Pre-Prostatectomy</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>